Wird geladen...
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs), represented by anti-CTLA-4 or anti-PD-1/anti-PD-L1 pathway antibodies, have led to a revolution in cancer treatment modalities. ICIs have unique clinical benefits, such as effectiveness against a broad range of tumor types, strong overall impact on survival, and...
Gespeichert in:
| Veröffentlicht in: | Cancer Manag Res |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6086110/ https://ncbi.nlm.nih.gov/pubmed/30122997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S167400 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|